ABSOLUTE PASI REDUCTIONS IN A PHASE 2B TRIAL OF THE SELECTIVE ORAL TYK2 INHIBITOR, TAK-279, IN MODERATE-TO-SEVERE PLAQUE PSORIASIS

被引：0
|
作者：
Green, Lawrence [1 ]
Ferris, Laura [2 ]
Moore, Angela [3 ,7 ,8 ]
Zirwas, Matthew [4 ]
Zhao, Yiwei [5 ]
Blau, Jessamyn [5 ]
Zhang, Wenwen [5 ]
Uy, Jonathan [5 ]
Winkelman, Warren [5 ]
Vender, Ronald [6 ]
机构：
[1] George Washington Univ, Sch Med, Rockville, MD USA
[2] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA
[3] Baylor Univ, Med Ctr, Dallas, TX USA
[4] Dermatologists Greater Columbus, Columbus, OH USA
[5] Takeda Dev Ctr Amer Inc, Cambridge, MA USA
[6] Dermatrials Res Inc, Hamilton, ON, Canada
[7] Arlington Res Ctr, Arlington, TX USA
[8] Arlington Ctr Dermatol, Arlington, TX USA
来源：
ACTA DERMATO-VENEREOLOGICA | 2024年 / 104卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P-069
引用
收藏
页数：102
相关论文
共 50 条
  • [1] TAK-279, A SELECTIVE ORAL TYK2 INHIBITOR, REDUCES BSA INVOLVEMENT IN A PHASE 2B TRIAL IN MODERATE-TO-SEVERE PLAQUE PSORIASIS
    Laquer, Vivian
    Kircik, Leon
    Sadick, Neil
    Weisman, Jamie
    Zhao, Yi- wei
    Blau, Jessamyn
    Zhang, Wenwen
    Uy, Jonathan
    Winkelman, Warren
    Gooderham, Melinda
    ACTA DERMATO-VENEREOLOGICA, 2024, 104
  • [2] Zasocitinib (TAK-279), a Selective Oral Tyrosine Kinase 2 Inhibitor, Reduces Body Surface Area Involvement in a Phase 2b Trial in Moderate-to-Severe Plaque Psoriasis
    Laquer, Vivian
    Kircik, Leon
    Sadick, Neil
    Weisman, Jamie
    Zhao, Yiwei
    Blau, Jessamyn
    Zhang, Wenwen
    Uy, Jonathan
    Winkelman, Warren
    Gooderham, Melinda
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 2301 - 2303
  • [3] INFLUENCE OF PATIENT BASELINE CHARACTERISTICS ON TAK-279 EFFICACY, A SELECTIVE ORAL TYK2 INHIBITOR: PHASE 2B TRIAL IN PSORIATIC ARTHRITIS
    Eder, Lihi
    Muensterman, Elena Tomaselli
    van de Heijde, Desiree
    Kivitz, Alan
    Trivedi, Mona
    Hong, Ting
    Rehman, Muhammad
    Weng, Haoling Holly
    Chen, Jingling
    Baraliakos, Xenofon
    ACTA DERMATO-VENEREOLOGICA, 2024, 104
  • [4] EFFICACY AND SAFETY OF TAK-279, A SELECTIVE, ORAL TYK2 INHIBITOR, IN A RANDOMIZED, PLACEBO-CONTROLLED PHASE 2B TRIAL IN PSORIATIC ARTHRITIS
    Kivitz, Alan
    Muensterman, Elena Tomaselli
    Kavanaugh, Arthur
    van der Heijde, Desiree
    Klimiuk, Piotr A.
    Valenzuela, Guillermo
    Dokoupilova, Eva
    Poirier, Gabrielle
    Srivastava, Bhaskar
    Dasen, Sue
    Zhang, Xinyan
    Trivedi, Mona
    Weng, Haoling Holly
    Hong, Ting
    Pothula, Peter
    Baraliakos, Xenofon
    ACTA DERMATO-VENEREOLOGICA, 2024, 104
  • [5] Zasocitinib (TAK-279), an oral, allosteric, highly selective TYK2 inhibitor, modulates disease-central cytokine pathways that define clinical response in patients with moderate-to-severe plaque psoriasis
    Krueger, James G.
    Garcet, Sandra
    Cheng, Jie
    Kumar, Sachin
    Tang, Jay
    Blau, Jessamyn
    Zhang, Wenwen
    Saha, Banishree
    Arunachalam, Vinayagam
    Heap, Graham A.
    Winkelman, Warren
    Thakker, Paresh
    Choudhury, Amit
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [6] An oral, selective TYK2 inhibitor, deucravacitinib, in patients with moderate-to-severe plaque psoriasis and baseline PASI ≤ 15 versus > 15
    Foley, P.
    Gooderham, M.
    Gordon, K.
    Thaci, D.
    Kundu, S.
    Kisa, R.
    Wei, Lan
    Banerjee, S.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2021, 62 : 55 - 55
  • [7] Assessment of Laboratory Parameter Changes in a Phase 2b Trial of Zasocitinib (TAK-279), an Oral, Highly Selective TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis
    Kavanaugh, Arthur
    Muensterman, Elena
    Lertratanakul, Apinya
    Hong, Ting
    Chen, Jingjing
    Pothula, Peter
    Mark, Ejim
    Kivitz, Alan
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 4770 - 4772
  • [8] Evaluating influence of baseline characteristics on efficacy of a selective oral TYK2 inhibitor, BMS-986165, in patients with moderate-to-severe plaque psoriasis in a Phase 2 trial
    Gordon, K.
    Papp, K.
    Gooderham, M.
    Thaci, D.
    Foley, P.
    Morita, A.
    Kundu, S.
    Kisa, R.
    Napoli, A.
    Banerjee, S.
    EXPERIMENTAL DERMATOLOGY, 2018, 27 : 29 - 30
  • [9] Evaluating the influence of baseline disease characteristics on efficacy of a selective oral TYK2 inhibitor, BMS-986165, in patients with moderate-to-severe plaque psoriasis in a phase 2 trial
    Gordon, Kenneth
    Papp, Kim
    Gooderham, Melinda
    Thaci, Diamant
    Foley, Peter
    Banerjee, Subhashis
    Kundu, Sudeep
    Kisa, Renata
    Napoli, Andrew
    Morita, Akimichi
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB59 - AB59
  • [10] MODULATION OF DISEASE-CENTRAL CYTOKINE PATHWAYS WITH TAK-279, A HIGHLY SELECTIVE ORAL TYK2 INHIBITOR, DEFINES CLINICAL RESPONSE IN PATIENTS WITH PSORIASIS
    Choudhury, Amit
    Garcet, Sandra
    Cheng, Jie
    Kumar, Sachin
    Tang, Jay
    Blau, Jessamyn
    Zhao, Yiwei
    Zhang, Wenwen
    Saha, Banishree
    Arunachalam, Vinu
    Heap, Graham A.
    Thakker, Paresh
    Krueger, James
    ACTA DERMATO-VENEREOLOGICA, 2024, 104
12345